Studien

ACTG A5187

AIDS Clinical Trials Group A5187

ACTG A5188

AIDS Clinical Trials Group A5188

ACTG A5199

AIDS Clinical Trials Group A5199

ACTG A5200

AIDS Clinical Trials Group A5200

ACTG A5201

AIDS Clinical Trials Group A5201

ACTG A5202

AIDS Clinical Trials Group A5202

ACTG A5206

AIDS Clinical Trials Group A5206

ACTG A5208

AIDS Clinical Trials Group A5208

ACTG A5208/OCTANE

AIDS Clinical Trials Group A5208/Optimal Combination Therapy After Nevirapine Exposure A5208

ACTG A5211

AIDS Clinical Trials Group A5211

ACTG A5214

AIDS Clinical Trials Group A5214

ACTG A5217

AIDS Clinical Trials Group A5217

ACTG A5221

AIDS Clinical Trials Group A5221

ACTG A5221 STRIDE

AIDS Clinical Trials Group A5221 STRIDE

ACTG A5224s

AIDS Clinical Trials Group A5224s

ACTG A5235

AIDS Clinical Trials Group A5235

ACTG A5241 (OPTIONS)

AIDS Clinical Trials Group A5241

ACTG A5244

AIDS Clinical Trials Group A5244

ACTG A5262

AIDS Clinical Trials Group A5262

ACTG A5267

AIDS Clinical Trials Group A5267

ACTG A5340

AIDS Clinical Trials Group A5340

ACTG A5359

AIDS Clinical Trials Group A5359

ACTG ALLRT

AIDS Clinical Trials Group Longitudinal Linked Randomized Trial

ACTG ALLRT/A5001

AIDS Clinical Trials Group Longitudinal Linked Randomized Trial/A5001

ACTG PEARLS

AIDS Clinical Trials Group PEARLS

ACTIB

Assessing Cognitive behavioural Therapy in Irritable Bowel

ACTICCA-2

Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma

ACTION

A Coronary disease Trial Investigating Outcome with Nifedipine GITS

ACTION

A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis

ACTION

Achieving Control Through Insulin plus Oral ageNts

ACTION

ACTinomycin eluting stent Improves Outcomes by reducing Neointimal hyperplasia

ACTION

ACTION: a phase III multicentre cluster randomised clinical trial to assess whether the 'Respecting Choices Program' improves quality of life and symptoms of patients with advanced cancer

ACTION

Acute Coronary Treatment and Intervention Outcomes Network

ACTION

Adjuvant Cytotoxic Chemotherapy in Older Women

ACTION

Advanced Cardiac Therapies Improving Outcomes Network

ACTION

Allies in Cardiovascular Trials Initiatives and Organized Networks

ACTION

Amiloride Clinical Trial In Optic Neuritis

ACTION

Anakinra in cerebral haemorrhage to target secondary injury resulting from neuroinflammation

ACTION

AntiCoagulaTlon cOroNavirus

ACTION

AntimiCrobial studies in TaIwan Operating Network

ACTION

Awareness, Care, and Treatment in Obesity maNagement

ACTION

Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke

ACTION

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy

ACTION

Single-center prospective registry using coronary CTA (ACTION registry) to improve the management of patients with suspected CAD, and examine the association between biomarkers of lipid metabolism, glucose metabolism, and inflammation with different phenotypes of CAD

ACTION CVT

Anticoagulation in the Treatment of Cerebral Venous Thrombosis

ACTION I

Aminoguanidine Clinical Trial In Overt type 2 diabetic Nephropathy I

ACTION II

Aminoguanidine Clinical Trial In Overt type 2 diabetic Nephropathy II

ACTION IO

Awareness, Care, and Treatment In Obesity maNagement-an International Observation

ACTION IV

AntiCoagulaTlon cOroNavirus-Coalition IV. Coalition COVID-19 Brazil IV

ACTION Teens

Awareness, Care & Treatment In Obesity Management - An International Observation Among Teens

ACTION-IO

Awareness, Care, and Treatment In Obesity maNagement-an International Observation

ActionICE

EvaluAtion of Predictive Value of Multisite Intracardiac EchoCardiography During Imaging of Structure and funCTION of Left Atrial Appendage in Comparison to Transesophageal Echocardiography

ACTISAVE

ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo

ACTIV in CHF

Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure

ACTIV-2/A5401

Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19

ACTIV-3/TICO LY-CoV555

Therapeutics for Inpatients with COVID-19

ACTIV-4a

Anti-thrombotics for adults hospitalized with COVID-19

ACTIV-4B

COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80

ACTIV-6

Accelerating COVID-19 Therapeutic Interventions and Vaccines

ACTIVATE

A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency

Vorherige Seite Nächste Seite